Background {#Sec1}
==========

Mechanical ventilation is commonly used to help normalize arterial blood gases in patients with acute hypercapnia but can also contribute to ventilator-induced lung injury (VILI). VILI results from over-distension of the lung, barotrauma, and alveolar damage caused by high volume ventilation \[[@CR1], [@CR2]\]. Extracorporeal CO~2~ removal (ECCO~2~R) provides a minimally invasive option to remove CO~2~ independently of the lungs and allow lung rest. ECCO~2~R has been used in patients with acute exacerbations of chronic obstructive pulmonary disease (ae-COPD) to avoid invasive mechanical ventilation, avoid intubation, or assist in extubation and in ventilator weaning \[[@CR3]--[@CR5]\]. In patients with moderate acute respiratory distress syndrome (ARDS), ECCO~2~R has been used in conjunction with lung protective or ultra-protective ventilator settings (tidal volume less than 6 mL/kg \[[@CR6]\] or 3 mL/kg \[[@CR7]\], respectively) to reduce VILI and correct acidosis \[[@CR7], [@CR8]\].

Contemporary ECCO~2~R devices use simplified designs, biocompatible coatings, and polymethylpentene fibers to reduce adverse events \[[@CR9]\]. Dual lumen catheters permit single site veno-venous (vv) cannulation and obviate the need for, and risks of, arterio-venous (av) cannulation. A 2016 epidemiological study shows that the trend is toward vv cannulation \[[@CR10]\]. The recent focus has been on improving the gas exchange efficiency of ECCO~2~R devices. Active mixing, blood acidification, electrodialysis, and carbonic anhydrase immobilization to the fiber surface are being explored in an effort to reduce fiber surface area and further lower blood flow rates \[[@CR11]--[@CR14]\].

ECCO~2~R utilizes similar principles as extracorporeal membrane oxygenation (ECMO), but with the main goal of removing CO~2~ in patients with otherwise sufficient oxygenation and at a fraction of ECMO blood flow rates. Lower blood flow rates are usable in ECCO~2~R due to the linear slope of the CO~2~ dissociation curve within the physiological pCO~2~ range. Thus, the amount of CO~2~ available per volume of blood decreases linearly with decreasing pCO~2~. Comparatively, the sigmoidal oxy-hemoglobin dissociation curve plateaus at pO~2~ values above 100 mmHg thereby limiting the amount of O~2~ that can be transferred to the blood \[[@CR9]\]. Clinically used ECCO~2~R blood flow rates vary from 180 to 1700 mL/min \[[@CR15]\] and are classified as either low-flow (\< 1 L/min) or mid-flow (1--2 L/min) with ECMO considered high-flow.

Proponents of mid-flow ECCO~2~R contend that higher blood flow rates are required to decrease the likelihood of thrombus formation and to attain the required CO~2~ removal rates. Both of these concerns stem from the velocity of the blood through the device. Research has shown that regions of a device with low-blood velocity are prone to thrombus formations \[[@CR16]\], and that increasing the velocity of the blood past the fibers increases the gas exchange efficiency \[[@CR17]\]. There are ways, however, to engineer an ECCO~2~R device with increased blood velocity independent of bulk blood flow and permit low-flow ECCO~2~R. The Hemolung RAS and the ultra-low flow ECCO~2~R device (ULFED) each use active mixing technology to increase the blood velocity at the fiber surface while still removing a clinically significant amount of CO~2~ \[[@CR12], [@CR18]\]. The Hemolung RAS device has been successfully used at blood flow rates below 500 mL/min to correct hypercapnia in patients \[[@CR19]--[@CR21]\]. The Low-Flow Pittsburgh Ambulatory Lung (LF-PAL) evaluated in this manuscript operates in the low-flow region and uses a narrow bundle cross sectional area to increase blood velocity past the fibers \[[@CR17]\].

Here, the performance of the LF-PAL as a low-flow ECCO~2~R device is evaluated through bench studies. The LF-PAL utilizes a 0.65 m^2^ bundle integrated with centrifugal pump into a highly compact device aimed at increasing patient mobility. The CO~2~ removal performance of the LF-PAL was modeled and then measured in vitro at blood flow rates up to 700 mL/min. Additionally, the hydrodynamic performance of the LF-PAL and the resistance of the Hemolung 15.5 Fr catheter were measured and used to determine the anticipated operating conditions. Lastly, in vitro hemolysis was evaluated in the 0.65 m^2^ LF-PAL and compared to two control circuits.

Methods {#Sec2}
=======

Device description {#Sec3}
------------------

The LF-PAL incorporates the hollow fiber membrane (HFM) bundle into a highly compact integrated pump-lung. The centrifugal pump drives blood flow from the patient, through the HFM bundle, and back to the patient via a dual lumen catheter located in the jugular vein. The impeller is magnetically coupled to, and driven by, an external motor. The device utilizes a 0.65 m^2^ cylindrical, stacked-type HFM bundle with a diameter of 1.75 in. The bundle is manufactured from polymethypentene fiber sheets (OXYPLUS, Membrana, Wuppertal, Germany) \[[@CR17]\]. This prototype device weighs 1850 g and is intended to have the option to be worn by the patient. The specific design and manufacturing details of the LF-PAL devices have been previously published \[[@CR22]\]. The device has previously been evaluated for high-flow adult oxygenation \[[@CR22]\], but not for low-flow CO~2~ removal.

CO~2~ removal model {#Sec4}
-------------------

The CO~2~ removal model was based on a previously published mass transfer correlation and assumes radially uniform flow through the bundle \[[@CR17], [@CR23]\]. Briefly, the overall CO~2~ mass balance is$$\documentclass[12pt]{minimal}
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Computational fluid dynamics (CFD) was used to analyze the hydraulic and hemodynamic aspects of the LF-PAL device as well as to ensure radially uniform flow through the fiber bundle as assumed by the mass transfer model. Blood flow velocities and pressures within the LF-PAL were modeled via laminar CFD analysis performed using ANSYS Fluent v17 (ANSYS, Canonsburg, PA). Blood was treated as a homogeneous incompressible fluid of density 988 kg/m^3^ and constant viscosity of 3.4 cP. The fiber bundle was modeled as porous media with a uniform viscous resistance \[[@CR23]\] of 1e9 m^−2^ and a fluid porosity \[[@CR25]\] of 0.58. The CFD mesh consisted of 5.7 M tetrahedral cells, and rotor motion was handled using a frozen relative motion frame of reference.

In vitro gas exchange {#Sec5}
---------------------

Gas exchange was performed in bovine blood collected from a local slaughterhouse and adhered to the ISO7199 standard \[[@CR26]\]. The blood was filtered (40 μm Pall Biomedical, Inc., Fajardo, PR), heparinized (30 U/mL), and treated with gentamicin (0.1 mg/mL). Blood was diluted to a hemoglobin of 12 ± 1 g/dL with phosphate-buffered saline. The test circuit (Fig. [1](#Fig1){ref-type="fig"}) consisted of a LF-PAL device, two 6-L compliant blood reservoirs and an Affinity oxygenator (Medtronic, Minneapolis, MN). The reservoir bags were submerged in a water bath to maintain blood temperature at 37 ± 1 °C. The blood was recirculated through a single reservoir while the Affinity oxygenator was used to balance the blood gases to venous conditions. Once the blood was conditioned, clamps were used to divert blood flow through the LF-PAL and into the empty, second reservoir. Blood gas measurements were taken before and after the LF-PAL and analyzed by a Rapidpoint 405 blood gas analyzer (Siemens, Deerfield, IL).Fig. 1Schematic of the single pass in vitro CO~2~ removal loop. Clamps are used to allow the reservoir filled with venous-conditioned blood to flow through the device and in to the empty second reservoir. Once the first reservoir empties, gases to the de-oxygenator are turned on and the blood is reconditioned to venous conditions

Blood flow rates ranged from 250 to 700 mL/min and were measured by an ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY). Hoffman clamps were used to simulate the resistance of the Hemolung 15.5 Fr dual lumen catheter (ALung Technologies, Pittsburgh, PA). The pressure across the device was monitored with a differential fluid pressure transducer (PX771-025DI; Omega Engineering, Inc., Stamford, CT). The normocapnic condition was tested at an inlet pCO~2~ of 45 ± 5 mmHg and sO~2~ of 65 ± 5%. The gas exchange rate at each flow rate was measured in triplicate.

The oxygen sweep gas flow rate was controlled by a gas flow controller (Fathom Technologies, Georgetown, TX) and ranged from 9 to 19.5 L/min. A WMA-4 CO~2~ analyzer (PP Systems, Amesbury, MA) measured the CO~2~ concentration in the sweep gas (*F*~CO2~) exiting the LF-PAL. Steady state was achieved when the CO~2~ concentration in the sweep gas changed by less than 10 ppm. CO~2~ removal rate (*v*CO~2~) was calculated according to Eq. [4](#Equ4){ref-type=""} and normalized to an inlet pCO~2~ of 45 mmHg (*v*CO~2~^\*^) according to Eq. [5](#Equ5){ref-type=""} \[[@CR27]\].$$\documentclass[12pt]{minimal}
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Hydrodynamic performance {#Sec6}
------------------------

The hydrodynamic performance of the 0.65 m^2^ LF-PAL was evaluated using an 8.5 g/L solution of carboxymethylcelluose sodium salt (CMC) (Sigma Aldrich, St. Louis, MO) as the working fluid. The viscosity of the CMC solution at 37 °C was 3.5 cP and verified using a capillary viscometer (Cannon Instrument Company, State College, PA). The LF-PAL was connected to a reservoir submerged in a 37 °C water bath. The rotation rate of the impeller was varied between 800 and 2000 RPM. Hoffman clamps placed at the inlet and outlet to the LF-PAL were used to vary the flow rate between 0 and 1.4 L/min. Pressure was measured at the inlet and outlet to the device using a differential fluid pressure transducer (PX771-025DI; Omega Engineering, Inc., Stamford, CT).

The anticipated catheter for use with the LF-PAL is the Hemolung 15.5 Fr dual lumen catheter. The catheter was inserted into a 1600-mL reservoir bag, and pressure was measured at the inflow and outflow ports of the catheter using a differential fluid pressure transducer. Pressure within the reservoir was assumed to be spatially uniform so that the resistance of the catheter may be calculated as the pressure difference between the inflow and outflow tubing connection ports of the catheter. Flow was driven by a Biomedicus BP-80 pump (Medtronic, Minneapolis, MN) and ranged between 100 and 900 mL/min.

In vitro hemolysis {#Sec7}
------------------

Bovine blood was collected and prepared as in the gas exchange experiments. The hemolysis test circuit consisted of the LF-PAL and the Hemolung 15.5 Fr dual lumen femoral catheter in order to reflect clinical use. The LF-PAL was tested at 500 mL/min.

The control circuit replaced the LF-PAL with a PediMag pump (Thoratec, Pleasanton, CA) and Minimax PLUS Hollow Fiber Oxygenator (Medtronic, Minneapolis, MN) and was run in parallel with the test circuit. The control circuit was operated at 1500 mL/min (3750--3800 RPM) to match the CO~2~ removal rates of the LF-PAL operated at 500 mL/min \[[@CR28]\]. Hoffman clamps were used to simulate inclusion of a 12 Fr arterial cannula (Medtronic Bio-Medicus Cannula \#96820-012) and 14 Fr venous cannula (Medtronic Bio-Medicus Cannula \#96830-014) \[[@CR29], [@CR30]\]. Both circuits contained an 800-mL compliant blood reservoir (Medtronic; Minneapolis, MN) submerged in a water bath to maintain blood temperature at 37 ± 2 °C.

Blood samples from each circuit were taken every 30 min over a 6-h period to measure plasma free hemoglobin (PfHb), hematocrit, and hemoglobin. Details of the sampling and PfHb measurement methods, calculation of the normalized index of hemolysis (NIH), and therapeutic index of hemolysis (TIH) have been previously published \[[@CR12], [@CR17]\]. Three independent trials were conducted for each circuit. The results of a second control (Medtronic Biomedicus BP-50, Minimax, and Medtronic Bio-Medicus Cannulas) are also included and methods have been previously described by our group \[[@CR12]\]. This second control, BP-50 control, was operated at the blood flow rate required for the Minimax to meet our 70 mL/min CO~2~ removal target.

Statistics {#Sec8}
----------

Calculations for statistical comparisons were completed using SPSS (IBM, Armonk, NY). A one-way ANOVA with Tukey HSD post hoc analysis was used to compare the mean TIH values and the mean NIH values. Levene's test was used to test for homogeneity of variances. The effect of device type was considered significant. Comparisons between the three TIH and NIH of the devices were considered significant at *p* \< 0.05.

Results {#Sec9}
=======

Model and in vitro CO~2~ removal {#Sec10}
--------------------------------

In vitro gas transfer results and model predictions of the 0.65-m^2^ bundle are shown in Fig. [2](#Fig2){ref-type="fig"}. The CO~2~ removal rate increased with increasing blood flow rate. The maximum CO~2~ removal rate of the LF-PAL was 105 ± 9.2 mL/min at a blood flow rate of 703 mL/min. The model predicted CO~2~ removal rates were within 7.7--15.4% of the experimental values.Fig. 2In vitro CO~2~ removal data of the LF-PAL. The model predicted CO~2~ removal rate is also plotted. The maximum CO~2~ removal rate for the LF-PAL was 105 mL/min. The model predicted the performance between 7.7--15.4% of the in vitro results

Pump requirements {#Sec11}
-----------------

The pressure generated by the 0.65 m^2^ LF-PAL device is shown in Fig. [3](#Fig3){ref-type="fig"}. The pressure requirements for operation with the 15.5 Fr dual lumen catheter are also shown in Fig. [3](#Fig3){ref-type="fig"}. The 0.65 m^2^ LF-PAL reached the required flow rate range of 250 to 700 mL/min at impeller rotation rates between 800 and 1800 RPM.Fig. 3The pressure generated by the LF-PAL at impeller rotation rates of 800, 1000, 1200, 1400, 1600, 1800, and 2000 RPM between 0 and 1 L/min. The pressure requirements of the 15.5 Fr dual lumen catheter are also shown

Typical CFD results shown in Fig. [4](#Fig4){ref-type="fig"} for the 0.65 m^2^ LF-PAL demonstrate adequate pressure generation and uniform flow distribution throughout the bundle. Generated pressure heads predicted by CFD were 51 mmHg for 850 RPM, 0.25 L/min and 265 mmHg for 1870 RPM, 0.70 L/min. The maximum shear stress predicted by CFD in the device for these operating conditions was located on the rotor surfaces and was less than 200 Pa. Flow through the fiber bundle was shown to have a very uniform distribution and exhibited no flow separation. For both operating conditions, the LF-PAL was shown to have the slowest flow occurring in the inflow elbow and the bundle inlet and outlet plenums.Fig. 4CFD analysis results for 850 RPM and 0.25 L/min showing (**a**) predicted pressure (mmHg) throughout the device, (**b**) fluid velocity (m/s) through the fiber bundle, and (**c**) near wall velocity magnitudes (m/s) on the device surfaces

In vitro hemolysis {#Sec12}
------------------

Table [1](#Tab1){ref-type="table"} provides the TIH and NIH values for the 0.65 m^2^ LF-PAL and control circuits. The rate of PfHb increase over time was linear (R^2^ \> 0.90) for the LF-PAL and control circuit. The TIH of the LF-PAL (0.08 ± 0.017 g/100 min), the Pedimag control (0.043 ± 0.0004 g/100 min), and the BP-50 control (0.123 ± 0.013 g/100 min) all significantly differed from one another (*p* \< 0.05). The NIH of the LF-PAL (0.158 ± 0.034 g/100 L), the Pedimag control (0.029 ± 0.003 g/100 L), and the BP-50 control (0.105 ± 0.012 g/100 L) all significantly differed from one another (*p* \< 0.05).Table 1In vitro hemolysis of the LF-PALDeviceFlow RateNIHTIH\[mL/min\]\[g/100 L\]\[g/100 min\]LF-PAL (0.65 m^2^)5000.158 ± 0.034^†^0.080 ± 0.017^‡^Pedimag control15000.029 ± 0.003^†^0.043 ± 0.004^‡^BP-50 control12500.105 ± 0.012^†^0.123 ± 0.013^‡†^Statistically significant (*p* \< 0.05) compared to other devices^‡^Statistically significant (*p* \< 0.05) compared to other devices

Discussion {#Sec13}
==========

Clinical evidence demonstrates that ECCO~2~R can prevent the need for intubation, allow for protective and ultra-protective lung ventilation, and aid in weaning patients from mechanical ventilation \[[@CR6], [@CR31]\]. Low-flow ECCO~2~R devices aim to provide minimally invasive, complementary treatment options for ae-COPD patients and patients with moderate ARDS requiring mechanical ventilation. This manuscript details the in vitro and computational characterization of the LF-PAL for ECCO~2~R. The LF-PAL is an integrated pump-lung designed to allow simplified patient ambulation while on ECCO~2~R. The LF-PAL removed up to 105 mL/min of CO~2~ thereby exceeding the 70 mL/min target and had acceptable hemolysis.

ECCO~2~R has been applied to a variety of clinical applications including weaning patients from mechanical ventilation, avoiding intubation, and permitting lung protective ventilation \[[@CR3]--[@CR5], [@CR7], [@CR8]\]. As a result of the range of clinical applications, the CO~2~ removal rate required for ECCO~2~R is not well defined. Additionally, CO~2~ removal is dependent on the total CO~2~ content of the blood. Hence, the degree of hypercapnia will affect the CO~2~ removal rate at a given blood flow rate. The CO~2~ removal rate, however, will proportionally increase with increases in pCO~2~. The CO~2~ removal target must therefore be reported as a percentage of the rate of metabolically produced CO~2~ or the pCO~2~ of the blood entering the device must be specified. Trahanas et al. provide a review of studies since 2009 of ECCO~2~R used in hypercapnic COPD patients and CO~2~ removal rates ranged from 80 to 160 mL/min \[[@CR32]\]. From this, the authors proposed that an ambulatory ECCO~2~R device must remove at least half of the metabolic CO~2~. Under normocapnic conditions, this would be approximately 100 mL/min. Commercial ECCO~2~R devices report removal rates of 20--40% of the metabolically produced CO~2~ \[[@CR33]--[@CR35]\]. Under normocapnic conditions, these rates are equal to 40--80 mL/min. Based on this data, we set 70 mL/min as the minimum target CO~2~ removal rate for the LF-PAL at normocapnia. The LF-PAL exceeded this target at low-flow ECCO~2~R blood flow rates. Recent, on-going, and upcoming ECCO~2~R clinical trials (XTRAVENT \[[@CR7]\], REST (NCT02654327), SUPERNOVA (NCT02282657), and VENT-AVOID (NCT03255057)) should provide a more defined CO~2~ removal target for devices in development.

Concerns with low-flow ECCO~2~R, compared to mid-flow, include inadequate CO~2~ removal and thrombus formation resulting from low-velocity regions within the device \[[@CR16]\]. To mitigate both of these effects, the LF-PAL uses a fiber bundle with a narrow cross sectional area to increase local blood velocities and achieve clinically significant CO~2~ removal. In addition, CFD results of the LF-PAL demonstrate uniform blood velocity through the bundle. Other low-flow devices use active mixing technology to increase local blood velocity in an effort to achieve required CO~2~ removal rates. The Hemolung incorporates a rotating core \[[@CR18]\], and the ULFED uses rotating impellers \[[@CR12]\]. The drawback is that too high of an increase in blood velocity may detrimentally increase hemolysis. The Hemolung, however, has been used in humans without causing clinically significant hemolysis, though no in vitro hemolysis data are available for comparison \[[@CR20]\].

At least one center has begun ambulating ECCO~2~R patients to reduce muscle deconditioning and allow for greater physical therapy \[[@CR3]\]. A compact device which does not require a saline infusion or vacuum pump, such as the LF-PAL, that could also be worn would simplify ambulation. Current, clinically used ECCO~2~R devices are portable, but are not designed to be worn by the patient \[[@CR36]--[@CR40]\]. The jugular cannulation and cartridge design of the Hemolung RAS permits ambulation. The device, however, must reside on the roller cart, which houses the required saline infusion and gas side vacuum pump and does not provide the option to be worn by the patient. The arterio-venous CO~2~ removal (AVCO2R) device is also under development as a wearable ECCO~2~R device \[[@CR41]\]. The av-cannulation of the AVCO2R, however, relies on the patient's cardiovascular system to drive blood flow. The CO~2~ removal rate is therefore dependent on the cardiac function of the patient \[[@CR42]\]. The vv-cannulation and pump-driven blood flow of the LF-PAL allows the clinician greater control of the extracorporeal blood flow and, in turn, the CO~2~ removal rate. The compact design and dual lumen cannulation of the LF-PAL lends itself to ambulation.

In this study the hemolysis of the LF-PAL was only evaluated at 500 mL/min. Shear stress within the circuit will increase as blood flow increases and likely result in elevated hemolysis at higher blood flow rates. Thus, when the LF-PAL is operated at the maximum blood flow rate, 700 mL/min, the TIH of the LF-PAL will likely increase, as would the TIH of the control circuit when operated at a higher blood flow rate. A limitation to the TIH is the lack of an established threshold value correlated to clinically significant hemolysis in vivo. Thus, in vitro studies are limited to a comparative assessment between two circuits. Future in vivo studies will thoroughly evaluate if the hemolysis generated by the LF-PAL is clinically significant in addition to any effect the device may have on platelet activation or end organ function.

Conclusion {#Sec14}
==========

Evidence demonstrating the benefits of partial CO~2~ removal by ECCO~2~R systems in conjunction with non-invasive ventilation or lung protective ventilation continues to grow. The LF-PAL provides the CO~2~ removal benefits of low-flow ECCO~2~R in a compact design. Future work will focus on 7-day in vivo studies to further characterize the LF-PAL performance and the effect of the device on the cardiopulmonary system.
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